Genotoxicity of Psychotropic Drugs in Experimental and Clinical Studies
Data from studies of the genotoxic activity of psychotropic drugs published over the past 25 years were analyzed. Information describing the genotoxicity of psychotropic drugs was found to be fragmentary and inconsistent, and the experimental conditions in which they were produced often fail to meet...
Gespeichert in:
| Veröffentlicht in: | Neuroscience and behavioral physiology 2023-06, Vol.53 (5), p.776-785 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 785 |
|---|---|
| container_issue | 5 |
| container_start_page | 776 |
| container_title | Neuroscience and behavioral physiology |
| container_volume | 53 |
| creator | Durnev, A. D. Eremina, N. V. Zhanataev, A. K. Kolik, L. G. |
| description | Data from studies of the genotoxic activity of psychotropic drugs published over the past 25 years were analyzed. Information describing the genotoxicity of psychotropic drugs was found to be fragmentary and inconsistent, and the experimental conditions in which they were produced often fail to meet accepted requirements. Among the 94 drugs considered, sufficient data for concluding that genotoxic properties are present or absent were found for only 9.6%. There is a need for a large-scale systematic reassessment of the genotoxicity of psychotropic drugs, especially first-generation drugs, based on modern methodology, including studies of mutagen-modifying activity. The desirability of monitoring the genotoxic status of patients treated with psychotropic drugs is emphasized, and this should contribute to an adequate assessment of the genotoxic risk of their use and determination of objective approaches to selecting drugs for safe therapy. The relevance of research to determine the role of primary DNA damage in the pathogenesis of mental illness is grounded. |
| doi_str_mv | 10.1007/s11055-023-01469-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2861025602</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2861025602</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1857-e164b48bada362f919f9781ef2422e5c2f70be2d8684cb0715eab64ffdbb84ac3</originalsourceid><addsrcrecordid>eNp9kNFKBCEUhiUK2rZeoKuBri11dNTL2LYtWCiooDtxHN1cNp10Btq3z5qgu64OB_7vP4cPgHOMLjFC_CpjjBiDiNQQYdpIyA_ADDNeQyHl6yGYISQ5RIzKY3CS8xYViAs0A6uVDXGIn974YV9FVz3mvXmLQ4q9N9VNGje58qFafvY2-XcbBr2rdOiqxc4Hb8ryNIydt_kUHDm9y_bsd87By-3yeXEH1w-r-8X1GhosGIcWN7SlotWdrhviJJZOcoGtI5QQywxxHLWWdKIR1LSIY2Z121DnurYVVJt6Di6m3j7Fj9HmQW3jmEI5qYhoMCKsKRLmgEwpk2LOyTrVl-912iuM1LcwNQlTJat-hCleoHqCcgmHjU1_1f9QXy4cbng</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2861025602</pqid></control><display><type>article</type><title>Genotoxicity of Psychotropic Drugs in Experimental and Clinical Studies</title><source>SpringerLink Journals</source><creator>Durnev, A. D. ; Eremina, N. V. ; Zhanataev, A. K. ; Kolik, L. G.</creator><creatorcontrib>Durnev, A. D. ; Eremina, N. V. ; Zhanataev, A. K. ; Kolik, L. G.</creatorcontrib><description>Data from studies of the genotoxic activity of psychotropic drugs published over the past 25 years were analyzed. Information describing the genotoxicity of psychotropic drugs was found to be fragmentary and inconsistent, and the experimental conditions in which they were produced often fail to meet accepted requirements. Among the 94 drugs considered, sufficient data for concluding that genotoxic properties are present or absent were found for only 9.6%. There is a need for a large-scale systematic reassessment of the genotoxicity of psychotropic drugs, especially first-generation drugs, based on modern methodology, including studies of mutagen-modifying activity. The desirability of monitoring the genotoxic status of patients treated with psychotropic drugs is emphasized, and this should contribute to an adequate assessment of the genotoxic risk of their use and determination of objective approaches to selecting drugs for safe therapy. The relevance of research to determine the role of primary DNA damage in the pathogenesis of mental illness is grounded.</description><identifier>ISSN: 0097-0549</identifier><identifier>EISSN: 1573-899X</identifier><identifier>DOI: 10.1007/s11055-023-01469-7</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Behavioral Sciences ; Biomedical and Life Sciences ; Biomedicine ; DNA damage ; Drugs ; Genotoxicity ; Mental disorders ; Neurobiology ; Neurosciences ; Psychotropic drugs</subject><ispartof>Neuroscience and behavioral physiology, 2023-06, Vol.53 (5), p.776-785</ispartof><rights>Springer Nature Switzerland AG 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c1857-e164b48bada362f919f9781ef2422e5c2f70be2d8684cb0715eab64ffdbb84ac3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11055-023-01469-7$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11055-023-01469-7$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids></links><search><creatorcontrib>Durnev, A. D.</creatorcontrib><creatorcontrib>Eremina, N. V.</creatorcontrib><creatorcontrib>Zhanataev, A. K.</creatorcontrib><creatorcontrib>Kolik, L. G.</creatorcontrib><title>Genotoxicity of Psychotropic Drugs in Experimental and Clinical Studies</title><title>Neuroscience and behavioral physiology</title><addtitle>Neurosci Behav Physi</addtitle><description>Data from studies of the genotoxic activity of psychotropic drugs published over the past 25 years were analyzed. Information describing the genotoxicity of psychotropic drugs was found to be fragmentary and inconsistent, and the experimental conditions in which they were produced often fail to meet accepted requirements. Among the 94 drugs considered, sufficient data for concluding that genotoxic properties are present or absent were found for only 9.6%. There is a need for a large-scale systematic reassessment of the genotoxicity of psychotropic drugs, especially first-generation drugs, based on modern methodology, including studies of mutagen-modifying activity. The desirability of monitoring the genotoxic status of patients treated with psychotropic drugs is emphasized, and this should contribute to an adequate assessment of the genotoxic risk of their use and determination of objective approaches to selecting drugs for safe therapy. The relevance of research to determine the role of primary DNA damage in the pathogenesis of mental illness is grounded.</description><subject>Behavioral Sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>DNA damage</subject><subject>Drugs</subject><subject>Genotoxicity</subject><subject>Mental disorders</subject><subject>Neurobiology</subject><subject>Neurosciences</subject><subject>Psychotropic drugs</subject><issn>0097-0549</issn><issn>1573-899X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kNFKBCEUhiUK2rZeoKuBri11dNTL2LYtWCiooDtxHN1cNp10Btq3z5qgu64OB_7vP4cPgHOMLjFC_CpjjBiDiNQQYdpIyA_ADDNeQyHl6yGYISQ5RIzKY3CS8xYViAs0A6uVDXGIn974YV9FVz3mvXmLQ4q9N9VNGje58qFafvY2-XcbBr2rdOiqxc4Hb8ryNIydt_kUHDm9y_bsd87By-3yeXEH1w-r-8X1GhosGIcWN7SlotWdrhviJJZOcoGtI5QQywxxHLWWdKIR1LSIY2Z121DnurYVVJt6Di6m3j7Fj9HmQW3jmEI5qYhoMCKsKRLmgEwpk2LOyTrVl-912iuM1LcwNQlTJat-hCleoHqCcgmHjU1_1f9QXy4cbng</recordid><startdate>20230601</startdate><enddate>20230601</enddate><creator>Durnev, A. D.</creator><creator>Eremina, N. V.</creator><creator>Zhanataev, A. K.</creator><creator>Kolik, L. G.</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QG</scope><scope>7QR</scope><scope>7TK</scope><scope>7TS</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>20230601</creationdate><title>Genotoxicity of Psychotropic Drugs in Experimental and Clinical Studies</title><author>Durnev, A. D. ; Eremina, N. V. ; Zhanataev, A. K. ; Kolik, L. G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1857-e164b48bada362f919f9781ef2422e5c2f70be2d8684cb0715eab64ffdbb84ac3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Behavioral Sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>DNA damage</topic><topic>Drugs</topic><topic>Genotoxicity</topic><topic>Mental disorders</topic><topic>Neurobiology</topic><topic>Neurosciences</topic><topic>Psychotropic drugs</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Durnev, A. D.</creatorcontrib><creatorcontrib>Eremina, N. V.</creatorcontrib><creatorcontrib>Zhanataev, A. K.</creatorcontrib><creatorcontrib>Kolik, L. G.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Physical Education Index</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Psychology Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>Neuroscience and behavioral physiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Durnev, A. D.</au><au>Eremina, N. V.</au><au>Zhanataev, A. K.</au><au>Kolik, L. G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Genotoxicity of Psychotropic Drugs in Experimental and Clinical Studies</atitle><jtitle>Neuroscience and behavioral physiology</jtitle><stitle>Neurosci Behav Physi</stitle><date>2023-06-01</date><risdate>2023</risdate><volume>53</volume><issue>5</issue><spage>776</spage><epage>785</epage><pages>776-785</pages><issn>0097-0549</issn><eissn>1573-899X</eissn><abstract>Data from studies of the genotoxic activity of psychotropic drugs published over the past 25 years were analyzed. Information describing the genotoxicity of psychotropic drugs was found to be fragmentary and inconsistent, and the experimental conditions in which they were produced often fail to meet accepted requirements. Among the 94 drugs considered, sufficient data for concluding that genotoxic properties are present or absent were found for only 9.6%. There is a need for a large-scale systematic reassessment of the genotoxicity of psychotropic drugs, especially first-generation drugs, based on modern methodology, including studies of mutagen-modifying activity. The desirability of monitoring the genotoxic status of patients treated with psychotropic drugs is emphasized, and this should contribute to an adequate assessment of the genotoxic risk of their use and determination of objective approaches to selecting drugs for safe therapy. The relevance of research to determine the role of primary DNA damage in the pathogenesis of mental illness is grounded.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><doi>10.1007/s11055-023-01469-7</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0097-0549 |
| ispartof | Neuroscience and behavioral physiology, 2023-06, Vol.53 (5), p.776-785 |
| issn | 0097-0549 1573-899X |
| language | eng |
| recordid | cdi_proquest_journals_2861025602 |
| source | SpringerLink Journals |
| subjects | Behavioral Sciences Biomedical and Life Sciences Biomedicine DNA damage Drugs Genotoxicity Mental disorders Neurobiology Neurosciences Psychotropic drugs |
| title | Genotoxicity of Psychotropic Drugs in Experimental and Clinical Studies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T16%3A45%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Genotoxicity%20of%20Psychotropic%20Drugs%20in%20Experimental%20and%20Clinical%20Studies&rft.jtitle=Neuroscience%20and%20behavioral%20physiology&rft.au=Durnev,%20A.%20D.&rft.date=2023-06-01&rft.volume=53&rft.issue=5&rft.spage=776&rft.epage=785&rft.pages=776-785&rft.issn=0097-0549&rft.eissn=1573-899X&rft_id=info:doi/10.1007/s11055-023-01469-7&rft_dat=%3Cproquest_cross%3E2861025602%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2861025602&rft_id=info:pmid/&rfr_iscdi=true |